HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
recainam
structure given in first source
Also Known As:
N-(2,6-dimethylphenyl)-N'-(3-(1-methylethylamino)propyl)urea; Wy 42362; Wy-42,362; Wy-42362; recainam hydrochloride; recainam tosylate; Urea, N-(2,6-dimethylphenyl)-N'-(3-((1-methylethyl)amino)propyl)-
Networked:
8
relevant articles (
3
outcomes,
1
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amides: 2428
Urea: 15015
Phenylurea Compounds: 1
recainam: 8
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Benzene Derivatives: 17
Phenylurea Compounds: 1
recainam: 8
Related Diseases
1.
Ventricular Premature Complexes (Premature Ventricular Contraction)
08/01/1987 - "
The antiarrhythmic efficacy and safety of oral recainam hydrochloride, a newly synthesized compound, were assessed during a 2-part study of 12 patients with frequent (at least 30/hour) ventricular premature complexes (VPCs).
"
08/01/1986 - "
The antiarrhythmic efficacy and safety of intravenous recainam, a newly synthesized compound displaying potent class I antiarrhythmic activity, were tested in 10 hospitalized patients with frequent (greater than 30/h) complex ventricular ectopic beats.
"
03/15/1993 - "
Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia.
"
04/01/1987 - "
Recainam, [N-2,6-dimethylphenyl-N'-3-(1-methylethyl-amino)propylurea] hydrochloride (Wy-42,362), is a new class I antiarrhythmic agent that has been shown to be very effective in suppressing premature ventricular contractions in humans.
"
2.
Ventricular Tachycardia
01/01/1989 - "
Electrophysiologic effects and efficacy of recainam for sustained ventricular tachycardia.
"
03/15/1993 - "
Antiarrhythmic and pharmacokinetic evaluation of intravenous recainam in patients with frequent ventricular premature complexes and unsustained ventricular tachycardia.
"
3.
Supraventricular Tachycardia
02/01/1991 - "
Electrophysiologic effects and antiarrhythmic efficacy of recainam in patients with supraventricular tachycardia.
"
02/01/1991 - "
To evaluate its electrophysiologic effects and antiarrhythmic efficacy in patients with recurrent supraventricular tachycardia (SVT), programmed electrical stimulation was performed in 10 patients before and after intravenous recainam (loading dose 0.8 mg/kg, infusion 1 mg/kg/h), and in four patients on oral recainam 1,200 mg/day.
"
4.
Ventricular Dysfunction
12/01/1987 - "
Based on these data, recainam can be safely administered as a loading dose followed by a continuous infusion in patients with stable cardiac disease without significant ventricular dysfunction.
"
5.
Heart Diseases (Heart Disease)
12/01/1987 - "
Recainam was administered as a loading dose of 3 mg/kg/40 minutes followed by a continuous infusion of 0.9 mg/kg/hr for 23 hours and 20 minutes to ten patients with cardiac disease and frequent PVCs (more than 30/hr).
"
12/01/1987 - "
Based on these data, recainam can be safely administered as a loading dose followed by a continuous infusion in patients with stable cardiac disease without significant ventricular dysfunction.
"
Related Drugs and Biologics
1.
propylurea
2.
Acecainide